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Anemia and Mortality in Heart Failure Patients
A Systematic Review and Meta-Analysis
Hessel F. Groenveld, MD,* James L. Januzzi, MD, FACC,† Kevin Damman, MD,*
Jan van Wijngaarden, MD, PHD,‡ Hans L. Hillege, MD, PHD,*
Dirk J. van Veldhuisen, MD, PHD, FACC,* Peter van der Meer, MD, PHD†
Groningen and Deventer, the Netherlands; and Boston, Massachusetts
Objectives The aim of this study was to assess the effect of anemia on mortality in chronic heart failure (CHF).
Background Anemia is frequently observed in patients with CHF, and evidence suggests that anemia might be associated
with an increased mortality.
Methods A systematic literature search in MEDLINE (through November 2007) for English language articles was per-
formed. In addition, a manual search was performed. We included cohort studies and retrospective secondary
analyses of randomized controlled trials whose primary objective was to analyze the association between ane-
mia and mortality in CHF. Of a total of 1,327 initial studies, we included 34 studies, comprising 153,180 pa-
tients. Information on study design, patient characteristics, outcome, and potential confounders were extracted.
Results Anemia was defined by criteria used in the original articles. Of the 153,180 CHF patients, 37.2% were anemic.
After a minimal follow-up of 6 months, 46.8% of anemic patients died compared with 29.5% of nonanemic pa-
tients. Crude mortality risk of anemia was odds ratio 1.96 (95% confidence interval: 1.74 to 2.21, p  0.001).
Lower baseline hemoglobin values were associated with increased crude mortality rates (r  0.396, p 
0.025). Adjusted hazard ratios showed an increased adjusted risk for anemia (hazard ratio 1.46 [95% confi-
dence interval: 1.26 to 1.69, p  0.001]). Subgroup analysis showed no significant difference between mortality
risk of anemia in diastolic or systolic CHF.
Conclusions Anemia is associated with an increased risk of mortality in both systolic and diastolic CHF. Anemia should,
therefore, be considered as a useful prognosticator, and therapeutic strategies aimed to increase hemoglobin
levels in CHF should be investigated. (J Am Coll Cardiol 2008;52:818–27) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.061s
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anemia is frequently observed in patients with chronic heart
ailure (CHF) (1–5). Prevalence of anemia depends both on
he severity of CHF and diagnostic criteria used to define it,
ut may be as high as 50% in selected patient cohorts (3,6). Of
ote, anemia is not only prevalent in the CHF population, but
everal studies in different patient populations found an asso-
iation with anemia, impaired cardiac function, more health
are utilization, and morbidity (1,7–11). In addition, numerous
tudies have assessed associations between anemia and mortal-
ty in CHF. Although most studies have documented higher
ortality rates in anemic CHF patients (1,3,12–17), some
rom the *Department of Cardiology, University Medical Center Groningen,
roningen, the Netherlands; †Division of Cardiology, Department of Medicine,
assachusetts General Hospital, Harvard Medical School, Boston, Massachusetts;
nd the ‡Department of Cardiology, Deventer Hospital, Deventer, the Netherlands.
r. Damman is supported by the Netherlands Heart Foundation (grant 2006B157).
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oundation (D97-017). Dr. van der Meer is supported by the Dutch Scientific
rganization (Rubicon grant: 825-07-011).g
Manuscript received February 19, 2008; revised manuscript received April 23,
008, accepted April 28, 2008.tudies report the absence of an adverse effect of anemia on
ortality in CHF (4,18–20). Therefore, better understanding
f the risk associated with the presence of anemia is necessary.
lucidating the contribution of anemia to mortality may lead
o a more accurate risk profiling in CHF patients, especially
ince several treatment options for anemia exist including
rythropoietin (EPO) and iron therapy (21,22). Ultimately,
his may lead to more effective therapeutic strategies from a
isk-benefit perspective in heart failure patients.
We, therefore, performed a rigorous systematic review
nd meta-analysis of published literature to more compre-
ensively assess the effect of anemia on mortality in CHF.
n addition, we explored whether subgroups of anemic
atients were at particularly high mortality risk.
ethods
earch strategy. We adhered to the MOOSE (Meta-
nalysis Of Observational Studies in Epidemiology) study
uidelines as previously published (23). To identify all relevant
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September 2, 2008:818–27 Anemia and Mortality in Heart Failuretudies, we performed a literature search in MEDLINE
ccessed by PubMed (1966 through November 2007). Two of the
uthors (H.G. and P.v.d.M.) developed a search strategy. To
dentify heart failure patients and anemia, we used both the
edical Subject Heading term (MeSH) and text word search
Table 1). In addition, we identified potentially relevant
tudies using a manual search of references lists from all
ligible studies and review articles. We consulted experts in
he field and searched the Institute for Scientific Informa-
ion Web of Sciences for publications that cited key
ublications.
tudy selection. We included cohort studies and retro-
pective secondary analyses of randomized controlled trials
hose primary objective was to analyze the association
etween anemia and mortality in CHF. Titles and abstracts
f all articles were evaluated and rejected on initial screen if
hey: 1) included subjects other than CHF patients; 2) had
o evaluation of hemoglobin (Hb) or hematocrit (Ht) levels;
) did not include all-cause mortality as outcome; 4) were
ublished only in abstract form; 5) included patients 18
ears old; 6) had follow-up of 6 months; or 7) were
ublished in another language than English.
After obtaining full reports of candidate studies, the same
eviewers independently assessed eligibility. Differences in
ata between the 2 reviewers were solved by rereviewing
orresponding articles, and the final set was agreed on by
onsensus. For studies in which not all data were published,
r data was insufficient, authors were addressed and asked
or additional information (3,4,12,19,24–26).
uality assessment and data abstraction. Each study was
valuated on quality according to the guidelines provided by
he United States Preventive Task Force (27) and published
ecommendations (28). The following characteristics were
ssessed: 1) duration of follow-up12 months; 2) reporting
oss of follow-up; 3) adjustment of possible confounders in
ultivariate analysis; 4) definition of anemia; 5) full speci-
cation of outcome; 6) study sample representative for
entioned population; 7) full specification of clinical and
emographic variables; 8) explanation of sample selection;
) temporality (Hb measured at baseline, not at time of
utcomes assessment); and 10) clear inclusion and exclusion
riteria. Studies were graded as poor quality if they met 5
erms Used in the Search Query
Table 1 Terms Used in the Search Query
Text words
Congestive heart failure, CHF, anemia, anaemia, hemoglobin, haemoglobin,
Hb, Hgb, hematocrit, haematocrit, Ht, Hct
MeSH terms
Heart failure, congestive; anemia; hemoglobin; hematocrit
Title and abstract search
Hemoglobins
Limits
English languagesHF  congestive heart failure; MeSH  Medical Subject Heading.riterion, fair if they met 5 to 7
riteria, and good if they met 8
riteria.
tatistical analysis. Random
ffects meta-analysis was con-
ucted to estimate the magni-
ude of risk associated with ane-
ia and all-cause mortality, as
easured by crude mortality
isks and unadjusted odds ratios
ORs). Where available, adjusted
azard ratios (HRs) were ex-
racted from Cox regression
nalysis. Adjusted risk estimates
ncluded those components as
ublished in final multivariate
odels for each study including confounding sociodemo-
raphic and clinical covariates. We performed tests of
eterogeneity between studies using a standard chi-square
est and I2 statistic. When heterogeneity was found to be
ignificant, pooled estimates based on random effects mod-
ls were reported. To examine sources of heterogeneity, we
onducted meta-regression analysis. Bias in published stud-
es was assessed using a funnel plot of study results against
tudy precision. We tested symmetry of the funnel plot by
he Egger’s test. Subgroup analysis was pre-defined for
ystolic versus diastolic CHF. Statistical significance was set
t p 0.05, and all statistical analyses were performed using
tata 9.0 (Stata Corp., College Station, Texas).
esults
escription of included studies. The electronic search
etrieved 1,327 eligible studies. Nonelectrical search identi-
ed 4 additional studies. On initial screening, 1,142 were
ejected, based on title. Of the 185 screened abstracts, 56
tudies were retrieved for detailed evaluation. Eventually 34
tudies were included in this meta-analysis (Fig. 1). Sec-
ndary analysis of the Val-HeFT (Valsartan Heart Failure
rial) study was described in 2 separate manuscripts: Anand
t al. (29) and Maggioni et al. (5). Crude mortality data
ere not published by Anand et al. (29), and for this reason
his study was excluded and the data of Maggioni et al. (5)
as used. In addition, 1 article described the effect of
nemia from 2 different studies (5). Both studies in this
ublished report were analyzed separately for the meta-
nalysis. The 34 included studies described a total of
53,180 patients (1,3–20,24–26,30–41). Characteristics of
he included studies are listed in Table 2, characteristics of
tudy populations are listed in Online Tables 1 and 2. Ten
ifferent definitions of anemia were used in the included
tudies. The World Health Organization (WHO) defini-
ion (Hb 13.0 g/dl for males and Hb 12.0 g/dl for
emales) was used in the majority of the studies. Table 3
isplays the different definitions of anemia in the included
Abbreviations
and Acronyms
CHF  chronic heart failure
CI  confidence interval
EPO  erythropoietin
ESP  erythropoiesis-
stimulating protein
Hb  hemoglobin
HR  hazard ratio
Ht  hematocrit
OR  odds ratio
WHO  World Health
Organizationtudies. Anemia, as defined in the original articles, was
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Anemia and Mortality in Heart Failure September 2, 2008:818–27resent in 37.2% of the CHF patients. Mean Hb from the
tudies ranged from 12.2 to 14.0 g/dl. Mean Ht values
anged from 36.6% to 42.7%.
eta-analysis findings. Among the 34 studies, mean
ollow-up ranged from a minimum of 6 months to a
aximum of 5 years. Crude mortality data were available in
3 studies. In one study, only the adjusted HR was available,
hereas the unpublished crude mortality data were lost after
urricane Katrina (25). Analysis of the crude mortality
evealed that 26,687 (46.8%) anemic patients died com-
ared with 28,274 (29.5%) nonanemic patients. This trans-
ated into an unadjusted mortality risk of OR 1.96 (95%
onfidence interval [CI]: 1.74 to 2.21, p 0.001) in anemic
HF patients compared with that in nonanemic CHF
atients (Fig. 2). When the 2 largest studies (Go et al. [3]
nd Kosiborod et al. [4]) were excluded, the mortality risk of
nemia was identical (OR: 1.95, 95% CI: 1.78 to 2.14, p 
.001). There was no evidence for publication bias. The
unnel plot did not show asymmetry (Fig. 3), which was
Figure 1 Flow Chart for Study Selection
CHF  chronic heart failure; Hb  hemoglobin.onfirmed by the Egger’s test (p  0.93). We found a pignificant heterogeneity between included studies (I2 
2.4%, p  0.001). Meta-regression analysis was performed
sing sociodemographic variables, medical history, drug use,
nd laboratory data as parameters. In this sensitivity analy-
is, excluding studies not adhering to the WHO definition
f anemia, no heterogeneity was observed (I2  36.5%, p 
S), yet the mortality risk remained (OR: 2.22, 95% CI:
.04 to 2.42, p  0.001). In addition, we found an inverse
nterstudy relationship between serum creatinine levels and
he effect of anemia on mortality. The effect of anemia on
ortality declined with higher serum creatinine levels.
hen assessing the gradual effect of baseline Hb values on
ortality, we found a linear trend between baseline Hb
easurements and mortality rates. Lower baseline Hb
alues were associated with increased annual mortality rates
r  0.396, p  0.025) (Fig. 4).
onfouding factors. In 127,437 patients (83.1% of the
otal included patients), reported mortality risks were ad-
usted for several sociodemographic and clinical covariates.
otential confounders that were adjusted for in the original
eports are shown in Table 4. In all but one study, age and
enal function were considered as potential confounders
this study included 178 patients) (33). When mortality risk,
stimated by adjusted HR, was combined, anemia remained
n independent predictor of mortality HR 1.46 (95% CI:
.26 to 1.69, p  0.001).
ubgroup analysis. In the subgroup analysis, we assessed
he difference between mortality risk of anemia in patients
ith systolic or diastolic CHF. Table 5 displays the defini-
ions of systolic and diastolic CHF used in the original
rticles. Studies or substudies in patients with only diastolic
HF included 20,924 patients of which 5,957 (28.5%)
atients died. In studies or substudies including only pa-
ients with systolic CHF, 40,025 patients were included, of
hich 12,423 (31.0%) died. The mortality risk associated
ith the presence of anemia was not significantly different
etween patients with systolic CHF (OR: 1.96, 95% CI:
.70 to 2.25, p 0.001) and diastolic CHF (OR: 2.09, 95%
I: 1.53 to 2.86, p  0.001).
iscussion
his is the first meta-analysis to address the relationship
etween anemia and mortality in patients with CHF. In our
nalysis, which examined more than 150,000 subjects,
nemia was frequently observed, found in over one-third of
HF patients. Presence of anemia in CHF patients is
ssociated with an increased mortality risk in patients with
ystolic as well as diastolic heart failure. The adverse effect
e found is substantial and significant. When assessing the
ortality risk by using multivariate analyses, anemia re-
ains an independent risk factor for mortality in CHF
atients.
revalence. In prior studies, it is observed that CHF is
ften accompanied by anemia. A wide range of anemia
revalence in CHF has been reported, ranging from 7% to
S821JACC Vol. 52, No. 10, 2008 Groenveld et al.
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Table 2 Study Characteristics
Author (Ref. #), Year Follow-Up n Patients End Points Major Exclusion Criteria Study Design Study
Al-Ahmad et al. (12), 2001 33.4 months 6,360 CHF, LVEF35%,
age 21 to 81 yrs
Mortality Recent MI, unstable angina,
sCR 2.5 mg/dl
Secondary analysis of
clinical trial
(SOLVD)
Good
Horwich et al. (9), 2002 5 yrs 1,061 Referred for heart
transplantation
evaluation
Mortality LVEF40%, NYHA class
III, no initial Hb, “dry”
weight, or adequate
follow-up
Retrospective,
observational,
single-center
cohort study
Good
McClellan et al. (38), 2002 2 yrs 633 Discharge diagnosis
of HF (ICD-9-CM)
Mortality Dialysis, death during
index hospitalization,
missing records
Retrospective,
observational,
multicenter cohort
study
Good
Tanner et al. (32), 2002 6months 193 Outpatient HF clinic at
university hospital
Mortality, heart
transplantation
Secondary anemia,
hemodialysis,
coronary intervention
last 3 months
Retrospective,
observational,
single-center
cohort study
Good
Kalra et al. (26), 2003 3 yrs 531 HF Mortality — Prospective
observational,
single-center
cohort study
Fair
Kosiborod et al. (39), 2003 1 yr 2,281 Principal discharge
diagnosis of HF
(ICD-9-CM),
age 65 yrs
Mortality,
hospitalization
Severe AoS or MiS, HF due
to acute illness, missing
Htc values, in-hospital
mortality
Retrospective,
observational,
multicenter chart
review
Good
Mozaffarian et al. (37), 2003 15months 1,130 LVEF 30% and
NYHA class IIIB or
IV HF symptoms
Mortality MI; unstable angina; stroke
or revascularization;
severe pulmonary,
renal, or hepatic disease,
sCR 3.0 mg/dl
Secondary analysis of
multicenter clinical
trial (PRAISE)
Good
Kerzner et al. (40), 2003 25months 367 Primary discharge
diagnosis of HF
Mortality — Retrospective,
observational,
single-center chart
review
Fair
Szachniewicz et al. (33), 2003 529 days 176 Admitted for HF Mortality Anemia due to known
secondary cause
Prospective,
observational,
single-center,
cohort study
Good
Sharma et al. (34), 2004 551 days 3,044 NYHA II to IV,
LVEF 40%,
age 60 yrs
Mortality Severe valvular disease,
recent PTCA, CABG,
MI, or unstable angina,
sCR 220 mol/l
Secondary analysis of
multicenter clinical
trial (ELITE II)
Good
Anand et al. (1), 2004 12.7 months 912 NYHA II to IV,
LVEF 30%,
age 18 to 55 yrs
Mortality,
hospitalization
Surgically correctable
causes of HF, other
serious illness, recent or
planned revascularization
Secondary analysis of
clinical trial
(RENAISSANCE)
Good
van der Meer et al. (30), 2004 1,100 days 74 Mild-to-severe CHF Mortality MI, CVA, severe renal
failure, valvular disease,
isolated systolic
dysfunction
Retrospective,
observational,
single-center
cohort study
Good
Ezekowitz et al. (24), 2005 962 days 791 Referred for
assessment and
management
of CHF
Mortality Missing Hb values Prospective
observational,
single-center
cohort study
Good
Maggioni et al. (5), Val-HeFT
2005
23months 5,010 Symptomatic HF
(NYHA II),
clinically stable
Mortality, time to
death, first
morbid event
Rapidly deteriorating HF,
acute MI, CAD likely to
require intervention,
unstable angina, recent
CVA, sCR 2.5 mg/dl
Secondary analysis of
a randomized
clinical trial
(Val-HeFT)
Good
Maggioni et al. (5), IN-CHF
2005
1 yr 2,411 Diagnosis of HF
according to
European Society
of Cardiology
Mortality — Retrospective,
observational,
multicenter cohort
study
Good
Gardner et al. (19), 2005 554 days 182 Advance HF, referred
for cardiac Tx
assessment
Mortality Age 16 yrs, pregnancy,
known malignancy
Prospective,
observational,
single-center cohort
study
FairContinued on next page
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Table 2 Continued
Author (Ref. #), Year Follow-Up n Patients End Points Major Exclusion Criteria Study Design Study
Rosolova et al. (35), 2005 4 yrs 508 Suspected HF Mortality — Retrospective,
observational,
multicenter cohort
study
Fair
Grigorian et al. (14), 2006 1.5 yrs 205 Admitted to tertiary
center for CHF
Mortality LVEF50% Retrospective,
observational,
Single-center
cohort study
Good
Kosiborod et al. (4), 2005 1 yr 50,405 Discharge diagnosis
of HF
Mortality,
hospitalization
for HF
Patients without documented
HF on admission, age
65 yrs, hemodialysis,
severe Aos, MiS,
Retrospective,
observational,
multicenter cohort
study
Good
Ralli et al. (16), 2005 1 yr 264 Referred to a
university hospital
for HF
management or
heart Tx
Mortality ACS or myocarditis,
LVEF 40%
Retrospective,
observational,
single-center
cohort study
Good
O’Meara et al. (36), 2006 37.7 months 2,653 Symptomatic (NYHA II
to IV) HF, for at
least 4 weeks,
age 18 yrs
Mortality sCR 265 mol/l,
symptomatic HT, MI, CVA
Secondary analysis of
clinical trial
(CHARM)
Good
Felker et al. (13), 2006 3.6 yrs 4,951 Symptomatic HF
(NYHA II) patients
undergoing cardiac
catheterization
Mortality Primary valvular heart
disease or congenital
heart disease
Retrospective,
observational,
single-center
cohort study
Fair
Terrovitis et al. (31), 2006 2 yrs 160 Symptomatic HF
(NYHA II to IV),
LVEF 35%
Mortality Recent MI or CABG,
unstable angina,
anticipated cardiac
surgery, sCR 3 mg/dl
Secondary analysis of
multicenter,
prospective clinical
trial
Good
Hebert et al. (25), 2006 436 days 410 LVEF40%, enrolled
in chronic HF
disease
managemant
program
Mortality Missing baseline values
of Hb, sCR
Retrospective,
observational,
single-center
cohort study
Fair
Formiga et al. (18), 2006 1 yr 103 Admitted for
symptomatic,
previously
unknown HF
Mortality,
hospitalization
for HF
Chronic advanced disease,
COPD, advanced renal
failure hemodialysis,
in-hospital mortality
Prospective,
observational,
single-center
cohort study
Good
Newton and Squire (15), 2006 1,257 days 528 Discharge diagnosis of
HF, without previous
hospitalization for
HF
Mortality Insufficient evidence of new
diagnosis of CHF
Retrospective,
observational,
single-center chart
review
Good
Komajda et al. (10), 2006 58months 2,996 NYHA class II to IV
and LVEF 35%
Mortality,
hospitalization
Recent change of
treatment, requirement
of IV medication
Secondary analysis of
clinical trial
(COMET)
Good
Go et al. (3), 2006 2 yrs 59,772 Diagnosed with CHF Mortality,
hospitalization
— Retrospective
observational,
longitudinal cohort
study
Good
Berry et al. (7), 2006 814 days 519 Diagnosed with CHF
or a treatment
for CHF
Mortality,
hospitalization,
HF
hospitalization
Primary or secondary
diagnosis of acute MI
Retrospective,
observational,
single-center chart
review
Fair
de Silva et al. (42), 2006 531 days 955 LVEF45%, CHF
enrolled in a
community-based
program
Mortality Pregnancy, dialysis,
disorders resulting in
anemia
Prospective,
observational,
single-center
cohort study
Fair
Maraldi et al. (11), 2006 12months 567 Diagnosed with HF,
age 65 yrs
Mortality,
physical
disability
Physical disability at
hospital discharge,
dementia, or severe
cognitive impairment
Secondary analysis of
longitudinal
observational study
Fair
Elabbassi et al. (8), 2006 1.3 yrs 437 Systolic or diastolic
CHF
Mortality,
hospitalization,
ED visit
No complete follow-up Prospective
observational,
single-center
cohort study
GoodContinued on next page
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September 2, 2008:818–27 Anemia and Mortality in Heart Failurever 50% (1–4,10,17,32,35). This range can be attributed to
ultiple factors, including the use of multiple definitions of
nemia. The WHO criteria was used in the majority of
tudies. In addition, administrational codes or arbitrary
oundary values to define anemia were also used. Studies
efining anemia with administrative codes (such as Inter-
ational Classification of Diseases, 9th Revision, codes)
ave clear limitations. The use of this coding system solely
elies on physicians to consider anemia as a possible
iagnosis leading to an underestimation of the preva-
ence. Therefore, we excluded in this meta-analysis stud-
es without measurements of actual Hb or Ht values. This
esulted in the exclusion of only one study (2). Results of
he current meta-analysis clearly indicate the need for
tandardized definitions of anemia in CHF patients. The
efinition of anemia appeared to be a major source of
eterogeneity. However, despite different definitions of
nemia in the present meta-analysis, the association with
ortality was robust, using different analysis strategies.
Definitions of Anemia Used in the Original Articl
Table 3 Definitions of Anemia Used in the O
Definition of Anemia
WHO Elabbassi et al. (8
et al. (10), For
al. (13), Ralli e
Gardner et al.
al. (40), Mozaf
Hb 11.5 g/dl Kalra et al. (26)
Hb 12.0 g/dl Varadarajan et al
Hb 12.3 g/dl Horwich et al. (9)
Hb 13.0 g/dl Sharma et al. (34
Hb 11.0 g/dl in women Maggioni et al. (V
and Hb 12.0 g/dl in men
Hb 11.5 g/dl in women Berry et al. (7), N
and 13.0 g/dl in men
Ht 35% Al-Ahmad et al. (
Ht 37% Kosiborod et al. 2
Ht 37% Terrovitis et al. (3
Ht 37% in women and
40% in men
Kosiborod et al. 2
ontinued
Table 2 Continued
Author (Ref. #), Year Follow-Up n Patients
Varadarajan et al. (6), 2006 5 yrs 2,246 Primary discharge of
diagnosis of CHF
Schou et al. (17), 2007 30months 345 Systolic HF
(LVEF 45%)
CS  acute coronary syndromes; AoS  aortic valve stenosis; CABG  coronary arterial bypass g
eart failure; COMET Carvedilol Or Metoprolol European Trial; COPD chronic obstructive pulmo
LITE II  Losartan Heart Failure Survival Study; F/U  follow-up; Hb  hemoglobin; HF  heart
evision, Clinical Modification; IN-CHF Italian Network—Congestive Heart Failure trial; IV intra
YHA  New York Heart Association functional class; PRAISE  Prospective Randomized Amlopid
andomized Etanercept North American Strategy to Study Antagonism of Cytokines; sCR  serumHt  hematocrit; WHO World Health Organization definition of anemia, Hb athophysiology. It is tempting to speculate about the
echanisms behind the increased mortality risk observed in
nemic CHF patients. Anemia may lead to an increased
ork load, resulting from an increased heart rate and stroke
olume (32,42,43). In response to the increased workload,
he heart undergoes “remodeling,” marked by left ventricu-
ar hypertrophy and dilation. This eventually may lead to
HF with an increased mortality risk. Also, renal failure, as
common comorbidity in CHF, might be implicated in the
athophysiology. CHF and renal failure are 2 entities that
re often seen together with prevalences ranging from 20%
o 40% (2,38,44–46). With meta-regression analysis, we
ound an inverse interstudy relationship between serum
reatinine levels and the effect of anemia on mortality.
owever, this result does not suggest that the mortality risk
eclines with higher creatinine levels. It merely illustrates a
tatistical decreasing effect of anemia on mortality with
ncreasing creatinine levels; the decline of the effect of
nemia on mortality can be the result of an increased
al Articles
Author (Ref. #)
aldi et al. (11), De Silva et al. (42), Go et al. (3), Komajda
t al. (18), Hebert et al. (25), O’Meara et al. (36), Felker et
6), Grigorian Shamagian et al. (14), Rosolova et al. (35),
zekowitz et al. (24), van der Meer et al. (30), Kerzner et
et al. (37), Schou et al. (17)
nand et al. (1), Szachniewicz et al. (33), Tanner et al. (32)
T) (5), Maggioni et al. (IN-CHF) (5)
and Squire (15)
39), McClellan et al. (38)
4)
End Points Major Exclusion Criteria Study Design Study
ortality,
hospitalization,
ED visit
CHF excluded with
Framingham criteria,
no ECG
Retrospective,
observational,
single-center,
chart review
Good
ortality — Prospective,
observational,
single-center
cohort study
Good
gery; CAD  coronary artery disease; CHARM  Candesartan in Heart Failure trial; CHF  chronic
ease; CVA cerebral vascular accident; ECG electrocardiogram; ED emergency department;
; HT  hypertension; Htc  hematocrit; ICD-9-CM  International Classification of Diseases, 9th
; LVEF left ventricular ejection fraction; MImyocardial infarction; MiSmitral valve stenosis;
rvival Evaluation trial; PTCA  percutaneous transluminal coronary angioplasty; RENAISSANCE 
inine; Tx  heart transplantation; Val-HeFT  Valsartan Heart Failure Trial.es
rigin
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hysiological standpoint, CHF can also cause renal failure
ue to a decreased cardiac output reducing renal perfusion
i.e., forward failure); subsequent renal failure may lead to
ecreased endogenous EPO levels and may ultimately
nduce anemia, leading to an increased cardiac workload
ompleting the vicious circle. Recently this has been called
he “cardio-renal-anemia syndrome” (48).
indings from intervention studies. Considering the in-
reased mortality risk caused by anemia, in heart failure as
ell as renal failure, trials have been designed in which
atients receive erythropoiesis-stimulating proteins (ESPs)
o increase Hb levels. The first intervention study to address
he efficacy of EPO in CHF patients was performed by
ilverberg et al. (49) in 32 patients. Correction of anemia
ith EPO and intravenous iron led to a significant increase
n left ventricular ejection fraction and decrease in New
ork Heart Association functional class, which was re-
Figure 2 Risk of All-Cause Mortality of Anemic Versus Nonanem
CHF  chronic heart failure. CI  confidence interval.ic CHF Patientsected by almost 90% reduction in the number of hospital-Figure 3 Funnel Plot for Publication Bias
OR  odds ratio.
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September 2, 2008:818–27 Anemia and Mortality in Heart Failurezations. A similar study showed that EPO treatment
ignificantly increased peak oxygen consumption and exer-
ise duration in patients with moderate-to-severe CHF
50). Recently, 2 substantially larger multicenter phase II
tudies evaluated the effects of darbepoetin (a long-acting
SP) on surrogate cardiovascular end points (51,52). Treat-
ent with darbepoetin was safe and effectively raised Hb.
oreover, it significantly improved clinical status; however,
o significant improvement in exercise tolerance could be
bserved.
However, recently several studies showed a potentially
armful effect of ESP treatment in patients with kidney
isease and malignancies. A meta-analysis in patients with
ancer-associated anemia showed an increased risk in ve-
Figure 4 Relationship Between Baseline
Hemoglobin and Annual Mortality
The area of each circle is proportional to the sample size in each cohort. The cen-
ter line shows the estimated mortality risk per year of lower baseline Hb values on
a continuous scale. The dotted lines represent the 95% confidence intervals.
otential Confounders of Included Studies
Table 4 Potential Confounders of Included Studies
Author (Ref. #) Number of Patients Age Gender
Elabbassi et al. (8) 437  
Maraldi et al. (11) 567  
Berry et al. (7) 519 
Newton and Squire (15) 528 
Hebert et al. (25) 410  
Felker et al. (13) 4,951 
Kosiborod et al. (4) 50,405  
Maggioni-V et al. (5) 5,010  
Maggioni-I et al. (5) 2,411  
van der Meer et al. (30) 74  
Szachniewicz et al. (33) 176
Mozaffarian et al. (37) 1,130  
Go et al. (3) 59,772  
Kalra et al. (26) 531 
Schou et al. (17) 345 ous thromboembolism and mortality associated with re-
ombinant EPO and darbepoetin administration (53). Fur-
hermore, concerns about the cardiovascular safety of ESP
n patients with kidney disease have been raised. Two
eparate studies showed that patients targeted to a higher
b level had an increased incidence of cardiovascular events
54,55). However, in these studies, no placebo groups were
ncluded. These studies were all performed in patients with
evere renal failure, and only a minority of patients suffered
rom heart failure. Consequently, the results of the studies
entioned in the preceding text cannot be extrapolated to
he CHF population.
Larger randomized studies are clearly needed to deter-
ine the impact on morbidity and mortality in CHF.
urrently, a large phase III morbidity and mortality trial,
he RED-HF (Reduction of Events with Darbepoetin
lfa in Heart Failure) trial (56), is being conducted to
nswer the question whether the use of ESPs in anemic
eart failure patients is beneficial. Besides ESP, intrave-
ous iron treatment is another intervention modality in
nemic CHF patients. Recently, 2 trials appeared show-
Renal Function
Severity of
Heart Failure Medical History Medication
  
  
 
 
  
  
   
   
   
  

  
   
 
 
efinitions of Systolic andiastolic HF Used in the Original Articles
Table 5 Definitions of Systolic andDiastolic HF Used in the Original Articles
LVEF (%)
Systolic CHF
Mozaffarian et al. (37), Anand et al. (1) 30
Komajda et al. (10), Terrovitis et al. (31) 35
Sharma et al. (34), Ralli et al. (16), Maggioni et al. (5),
Kerzner et al. (40), Kosiborod et al. (4), O’Meara et al. (36),
Felker et al. (13)
40
Schou et al. (17) 45
Diastolic CHF
Kerzner et al. (40), Kosiborod et al. (4), O’Meara et al. (36),
Felker et al. (13)
40
Grigorian Shamagian et al. (14) 50
bbreviations as in Table 2.
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evels in patients with CHF. Moreover, they showed an
mproved exercise capacity and decreased NT-proBNP
evels (57,58). Further research is needed to study the
ffect of intravenous iron on morbidity and mortality in
nemic CHF patients.
tudy limitations. Limitations of meta-analyses include
ifferences in designs and populations used in included
rials, quality of studies, and heterogeneity (59). However,
he quality of all studies was graded according to published
uidelines and all met at least 7 of 12 criteria.
Evaluation of anemia was only at baseline in all
ncluded studies. Tang et al. (60) recently reported a
tudy with serial hemoglobin measurements and showed
hat persistent anemia has a larger effect on mortality
han transient anemia. No evaluation of Hb was per-
ormed during the studies; thus, it remains unknown
hether anemia in the included studies was persistent or
ransient. Furthermore, heterogeneity in our study is
ubstantial and can be attributed to differences in dura-
ion of follow-up, type of patients included, study design,
nd definition of anemia. Definition of anemia was a
ajor cause of heterogeneity. When mortality risk was
ssessed using studies that defined anemia by WHO
riteria, heterogeneity was no longer significant, while
he increased mortality risk caused by anemia remained.
urthermore, our meta-analysis could not exclude resid-
al confounding from studies in the adjusted analyses,
lthough most studies adjusted for many known major
onfounders. However, this limitation emphasizes the
nability of our analysis to prove causality.
Previously, it has been argued that a larger meta-analysis
e.g., 1,000 events) is clinically more meaningful (59); our
tudy, which includes over 50,000 events, is therefore of
articular note. Besides the overall size, the individual
tudies in the present analysis were of considerable size, with
4 including more than 1,000 patients. These strengths
ake our findings all the more firm.
onclusions
nemia is present in one-third of the CHF population
nd is an independent risk prognosticator for mortality in
ubjects so affected, irrespective of a systolic versus
iastolic etiology of CHF. Further research is needed to
ssess the effect of correcting anemia in CHF patients.
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